Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2018-03-12 Director's Dealing
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-03-12 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-12 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-12 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an Equity Underwriting Agreement related to a stock and warrant offering, including details about the shares, warrants, pricing, underwriters, and legal opinions. This is a clear update on the company's capital raising activities and financing. It is not a full financial report, earnings release, or management discussion, but rather a specific announcement about financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2018-03-07 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a public offering of common stock and warrants by SCYNEXIS, Inc. It includes offering terms, underwriting details, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing used in securities offerings. The content focuses on capital raising activities, including share issuance and warrants, and does not contain financial statements or earnings data. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2018-03-06 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus related to an offering of common stock and warrants by SCYNEXIS, Inc. It includes information about the securities being offered, risk factors, use of proceeds, underwriting details, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing used in securities offerings. This type of document is related to capital raising activities and financing updates rather than financial results, management changes, or regulatory filings unrelated to financing. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive offering document.
2018-03-05 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.